Company research
Accustem Sciences Inc.
CIK 1850767Updated Sep 24, 2026
SecurityACUT · OTC · equity
Name history
AccuStem Sciences Ltd · through Jul 1, 2021
ACUT price & chart
Loading TradingView…
OTC:ACUT on TradingView ↗In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 1,549,446Source | 50,851Source | 133,897Source | 939,689Source |
| Property, Plant and EquipmentUSD | — | 418Source | 4,048Source | 7,678Source |
| Current assets: | ||||
| Assets, CurrentUSD | 49,446Source | 50,433Source | 129,849Source | 932,011Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 4,951,071Source | 3,364,075Source | 2,245,477Source | 1,079,239Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 16,072Source | 12,100Source | 11,346Source | 11,346Source |
| Additional Paid in CapitalUSD | 6,365,446Source | 4,701,723Source | 4,399,019Source | 4,320,385Source |
| Retained Earnings (Accumulated Deficit)USD | -9,783,143Source | -8,027,047Source | -6,521,945Source | -4,471,281Source |
| Stockholders' Equity Attributable to ParentUSD | -3,401,625Source | -3,313,224Source | -2,111,580Source | -139,550Source |
| Liabilities and EquityUSD | 1,549,446Source | 50,851Source | 133,897Source | 939,689Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 4,951,071Source | 3,364,075Source | 2,245,477Source | 1,079,239Source |
| Accounts Payable, CurrentUSD | 703,812Source | 804,615Source | 578,378Source | 311,834Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 1,875Source | 164,053Source | 156,434Source | 518,625Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 88,695Source | 69,718Source | 78,634Source | 133,889Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -100,802Source | 226,237Source | 266,544Source | -76,846Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -850,389Source | -664,066Source | -1,615,643Source | -1,806,053Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | -10,999Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | 10,999Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 859,271Source | 647,632Source | 903,146Source | 2,551,030Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 8,882Source | -16,434Source | -712,497Source | 733,978Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 1,854Source | 3,392Source | 7,192Source | 7,474Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 76,634Source | — |
| DepreciationUSD | 418Source | 3,630Source | 3,630Source | 3,321Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | 66,981Source |
| General and Administrative ExpenseUSD | 1,475,082Source | 1,366,778Source | 1,911,001Source | 3,479,486Source |
| Net Income (Loss) Attributable to ParentUSD | -1,756,096Source | -1,505,102Source | -2,050,664Source | -3,746,419Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -1,756,096Source | -1,505,102Source | -2,050,664Source | -3,746,419Source |
| Operating ExpensesUSD | 1,756,096Source | 1,505,102Source | 2,050,664Source | 3,746,419Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 2,675,940Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 8,469Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -1,756,096Source | -1,505,102Source | -2,050,664Source | -3,746,419Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -1,756,096Source | -1,505,102Source | -2,050,664Source | -3,746,419Source |
| Net Income (Loss) Attributable to ParentUSD | -1,756,096Source | -1,505,102Source | -2,050,664Source | -3,746,419Source |
| Earnings Per Share, BasicUSD per share | -0.12Source | -0.13Source | -0.18Source | -0.34Source |
| Earnings Per Share, DilutedUSD per share | -0.12Source | -0.13Source | -0.18Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | 15,233,501Source | 11,435,362Source | 11,346,535Source | 11,016,165Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 15,233,501Source | 11,435,362Source | 11,346,535Source | — |
| Additional Financial Items | ||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | 66,981Source |
| General and Administrative ExpenseUSD | 1,475,082Source | 1,366,778Source | 1,911,001Source | 3,479,486Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -1,756,096Source | -1,505,102Source | -2,050,664Source | -3,746,419Source |
| Operating ExpensesUSD | 1,756,096Source | 1,505,102Source | 2,050,664Source | 3,746,419Source |
| Research and Development ExpenseUSD | 281,014Source | 138,324Source | 139,663Source | 266,933Source |